Specific Serotonin Reuptake Inhibition in Major Depressive Disorder Adversely Affects Novel Markers of Cardiac Risk
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
There exists a growing body of evidence linking depression with cardiovascular events, although the mechanisms responsible remain unknown. We investigated the role of the autonomic nervous system and inflammation in the link between coronary heart disease and major depressive disorder (MDD), and examined the cardiac risk modification following pharmacological treatment of depression. We measured cardiac baroreflex function, heart rate variability, pulse pressure and high sensitivity C-reactive protein (hsCRP), all of which have an impact on cardiac risk, pre- and post-treatment in 25 patients with MDD, with no history of coronary heart disease, and in 15 healthy subjects. Treatment consisted of selective serotonin reuptake inhibitors for approximately 12 weeks. No significant differences were observed between untreated MDD patients and healthy subjects in blood pressure, heart rate, baroreflex sensitivity or heart rate variability. Pulse pressure and hsCRP, however, were significantly elevated in patients with MDD prior to treatment (p=0.023 and p=0.025, respectively). Moreover, while pharmacotherapy was effective in alleviating depression, surprisingly, each of cardiac baroreflex function, heart rate variability, pulse pressure and hsCRP was modified (p<0.05) in a manner likely to increase cardiac risk. In conclusion, this study demonstrated higher pulse pressure and hsCRP plasma levels in patients with MDD, which might contribute to increased cardiac risk. Following treatment vagal activity was reduced, as indicated by reductions in baroreflex sensitivity and heart rate variability, accompanied by increases in pulse pressure and plasma hsCRP levels. Mechanisms potentially responsible for generating cardiac risk in patients treated with selective serotonin reuptake inhibitors may need to be therapeutically targeted to reduce the incidence of coronary heart disease in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pagani, M., Lombardi, F., Guzzetti, S., Rimoldi, O., Furlan, R., Pizzinelli, P., Sandrone, G., Malfatto, G., Dell'Orto, S., & Piccaluga, E. (1986) · Circulation Research · doi:10.1161/01.res.59.2.178 · Cited by 4,130 · cited 1×
“Cardiac baroreflex function was assessed using both cross spectral analysis (21, 22) and the sequence method (23).”
MethodTracey, K. J. (2002) · Nature · doi:10.1038/nature01321 · Cited by 3,728 · cited 1×
“Dubbed the “cholinergic anti-inflammatory pathway,” efferent vagal activity results in acetylcholine release which, in turn, suppresses the inflammatory response (24).”
BackgroundRovere, M. T. L., Bigger, J. T., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11144-8 · Cited by 3,120
Rosengren, A., Hawken, S., Ôunpuu, S., Sliwa, K., Zubaid, M., Almahmeed, W. A., Blackett, K. N., Sitthi-amorn, C., Sato, H., & Yusuf, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17019-0 · Cited by 2,414
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
The Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Symptoms of depression, acute myocardial infarction, and total mortality in a community sample
Barefoot, J. C., & Schroll, M. (1996) · Circulation · doi:10.1161/01.cir.93.11.1976 · Cited by 850
Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00028-l · Cited by 622
“Stress” and coronary heart disease: psychosocial risk factors
Bunker, S. J., Colquhoun, D. M., Esler, M. D., Hickie, I. B., Hunt, D., Jelinek, V. M., Oldenburg, B. F., Peach, H. G., Ruth, D., Tennant, C. C., et al. (2003) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05193.x · Cited by 560
Self-citationAlesci, S., Martinez, P. E., Kelkar, S., Ilias, I., Ronsaville, D. S., Listwak, S. J., Ayala, A. R., Licinio, J., Gold, H. K., Kling, M. A., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1667 · Cited by 372
Sauer, W. H., Berlin, J. A., & Kimmel, S. E. (2003) · Circulation · doi:10.1161/01.cir.0000079172.43229.cd · Cited by 247 · cited 1×
“chance of developing myocardial infarction (42).”
Cited by
Kemp, A. H., Quintana, D. S., Gray, M. A., Felmingham, K. L., Brown, K., & Gatt, J. M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.012 · Cited by 1,286
Alvares, G. A., Quintana, D. S., Hickie, I. B., & Guastella, A. J. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140217 · Cited by 503
A meta-analysis of heart rate variability in major depression
Koch, C., Wilhelm, M., Salzmann, S., Rief, W., & Euteneuer, F. (2019) · Psychological Medicine · doi:10.1017/s0033291719001351 · Cited by 474
Grippo, A. J., & Johnson, A. K. (2009) · Stress · doi:10.1080/10253890802046281 · Cited by 452
Lim, M. H., Eres, R., & Vasan, S. (2020) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-020-01889-7 · Cited by 438
Metadata
- Authors
- DAWOOD, T., LAMBERT, E. A., BARTON, D. A., LAUDE, D., ELGHOZI, J.-L., ESLER, M. D., HAIKERWAL, D., KAYE, D. M., HOTCHKIN, E. J., & LAMBERT, G. W.
- Venue
- Hypertension Research
- Publisher
- Japanese Society of Hypertension
- Published
- 2007
- Volume
- 30
- Issue
- 4
- Pages
- 285-293
- ISSN
- 0916-9636 (ISSN-L)
- 1348-4214
- OpenAlex
- W1981432732
- Cited by
- 75
- References
- 12
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.